- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00775203
A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.
April 24, 2012 updated by: Labopharm Inc.
The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This two-arm, multicentre, randomized, placebo-controlled, double-blind, parallel-design study consisted of a baseline phase (screening and wash-out) and a double-blind randomized phase (randomization to Trazodone Contramid® OAD or placebo).
The total study duration including wash-out of prohibited medications was approximately 11 weeks; the total duration of the randomized phase was 8 weeks (titration: 2 weeks + treatment: 6 weeks).
Study Type
Interventional
Enrollment (Actual)
412
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y2H4
-
Penticton, British Columbia, Canada, V2A5C8
-
-
Newfoundland and Labrador
-
Mount Pearl, Newfoundland and Labrador, Canada, A1N1W7
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L5G8
-
Oakville, Ontario, Canada, L6J3J4
-
-
Quebec
-
Gatineau, Quebec, Canada, J9A1K7
-
Saint-Leonard, Quebec, Canada, H1S3A9
-
Sherbrooke, Quebec, Canada, J1H4J6
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35216
-
-
Arizona
-
Mesa, Arizona, United States, 85206-4616
-
-
California
-
Beverly Hills, California, United States, 90210
-
Burbank, California, United States, 91506
-
San Diego, California, United States, 92108
-
-
Colorado
-
Denver, Colorado, United States, 80212
-
-
Florida
-
Gainesville, Florida, United States, 32607
-
Hialeah, Florida, United States, 33013
-
Jacksonville, Florida, United States, 32216
-
Orlando, Florida, United States, 32806
-
Tampa, Florida, United States, 33613
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
-
Marietta, Georgia, United States, 30060
-
Smyrna, Georgia, United States, 30080
-
-
Illinois
-
Libertyville, Illinois, United States, 60048
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
-
-
Kansas
-
Overland Park, Kansas, United States, 66212
-
-
New Jersey
-
Clementon, New Jersey, United States, 08021
-
-
New York
-
Brooklyn, New York, United States, 11235
-
New York, New York, United States, 10021
-
New-York, New York, United States, 10021
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
-
Cincinnati, Ohio, United States, 45242
-
Dayton, Ohio, United States, 45408
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73103
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19149
-
-
Texas
-
Bellaire, Texas, United States, 77401
-
San Antonio, Texas, United States, 78229
-
-
Vermont
-
Woodstock, Vermont, United States, 05091
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males or females.
- Aged 18 years or older.
- Fulfills Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for Unipolar Major Depressive Disorder (MDD) (Axis I) as confirmed by the Mini-International Neuropsychiatric Interview (MINI).
- The primary DSM-IV Axis I diagnosis should be MDD (296.22, 296.23, 296.32, 296.33); any subject meeting criteria for another, non excluded Axis I disorder, must demonstrate MDD as the primary disorder.
- The current episode of MDD should have lasted for a minimum of 1 month, whether the patient has been diagnosed with one single or recurrent episodes.
- Presence of dysphoria for most days over the past four weeks.
- Montgomery-Åsberg Depression Rating Scale (MADRS) total score of at least 26 at screening and baseline.
- Oral and written language comprehension at a level sufficient to comply with the protocol and to complete study-related materials.
- Sign and date a written Informed Consent Form (ICF) approved by a Research Ethic Board (REB) which has also been signed and dated by the Investigator prior to study participation.
Exclusion Criteria:
- DSM-IV Major Depressive Disorder Specifiers: [a] With Catatonic Features; [b] With Postpartum Onset; [c] With Seasonal Pattern;
- Presence of any of the following DSM-IV Axis I disorders: generalized anxiety disorder, panic disorder, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, eating disorder, bipolar disorder, alcohol/substance abuse or dependence (caffeine and nicotine allowed), any psychotic disorder.
- Depression secondary to stroke, cancer or other severe medical illnesses.
- Positive urine drug screen at screening visit.
- History or present condition of any DSM-IV Axis II disorder.
- History of treatment refractory major depressive episodes defined as incomplete or no therapeutic response to two prior courses of at least one month of conventional antidepressant drug treatment in adequate dosages.
- Currently in psychotherapy (at least one session in the past month with a plan for continuing) with a licensed/registered/certified mental health provider, marriage counselor, or family therapist.
- Meet criteria for high suicide risk on the MINI suicide scale, or in the opinion of the investigator is inappropriate for the trial due to clinically significant suicidal or homicidal potential.
- Require hospitalization for treatment of the current episode of depression.
- Uncorrected hypo- or hyperthyroidism.
- A history of seizures other than pediatric febrile seizure.
- A history of cardiac arrythmias requiring therapy.
- A history of myocardial infarction within 1 year before screening.
- Clinically significant abnormal findings of Electrocardiography (ECG), laboratory parameters.
- Unwilling to discontinue use of any antidepressants, including herbal remedies, for a minimum of 5 drug half-lives prior to screening.
- Unwilling to discontinue use of prohibited medications for a minimum of 5 drug half-lives prior to screening.
- Treatment within the last 3 weeks with Monoamine Oxidase (MAO) inhibitors.
Use of the following concomitant treatment during the study:
- medications causing QT prolongation (e.g. amiodarone, droperidol, erythromycin).
- medications causing PR prolongation (e.g. digoxin).
- Anti -psychotics (e.g. haloperidol).
- protease inhibitors such as ritonavir and indinavir.
- Hormonal treatment (e.g. estrogen, oral contraceptives) which has started within 3 months of study entry.
- Treatment with another investigational agent within the last 30 days.
- Known and documented allergy to trazodone or any structurally similar drugs.
- Previous failure of treatment with trazodone, or previous discontinuation of treatment with trazodone due to Adverse Events.
- Bowel disease causing malabsorption.
- Serious, unstable illnesses during the 3 months before screening including but not limited to: hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic or hematological disease.
- Pregnant or lactating, or is of childbearing potential and not willing to use an approved method of contraception.
- Significant liver disease, defined as active hepatitis or elevated liver enzymes >3 times the upper boundary of the normal range.
- Significant renal disease, defined as Blood Urea Nitrogen (BUN) and/or creatinine >3 times the upper boundary of the normal range clearance.
- Any other condition that, in the opinion of the investigators, would adversely affect the patient's ability to complete the study or its measures.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: Trazodone Contramid Once A Day (OAD)
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hamilton Depression Scale (HAMD-17) Total Score From Baseline
Time Frame: Baseline to Week 8
|
The Hamilton Depression Rating Scale 17 items [HAMD-17] is a 17-item scale that evaluates depressed mood, vegetative and cognitive symptoms of depression, and co-morbid anxiety symptoms.
The 17 items are rated on either a 5-point (0-4) or a 3-point (0-2) scale.
In general, the 5 point scale items use a rating of 0=absent; 1=doubtful to mild; 2=mild to moderate; 3=moderate to severe; 4=very severe.
The 3-point scale items use a rating of 0=absent; 1=probable or mild; 2=definite.
The total HAMD-17score ranges from 0 (not ill) to 52 (severely ill).
|
Baseline to Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HAMD-17 Responders at Each Visit
Time Frame: Weeks 1, 2, 3, 4, 6, 8
|
Number of patients who show a response (defined as at least a 50% reduction from baseline in HAMD-17 score) at each post-baseline visit.
|
Weeks 1, 2, 3, 4, 6, 8
|
HAMD-17 Remitters at Each Visit
Time Frame: Weeks 1, 2, 3, 4, 6, 8
|
Number of patients who are remitters (defined as patients who achieved a HAMD-17 total score ≤7) at each post-baseline visit.
|
Weeks 1, 2, 3, 4, 6, 8
|
Change in HAMD-17 Depressed Mood Item (Item 1) Score From Baseline to Each Visit
Time Frame: Baseline to Weeks 1, 2, 3, 4, 6, 8
|
Change from baseline in the HAMD-17, item 1: Depressed Mood item, at each post-baseline visit.
The Depressed Mood item is rated on a 5-point scale ranging from rating of 0=absent; to 4=very severe.
|
Baseline to Weeks 1, 2, 3, 4, 6, 8
|
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline
Time Frame: Baseline to Week 8
|
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10 item clinician-administered depression rating scale.
The 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) are rated on a scale ranging from 0 (low severity/difficulty) to 6 (high severity/difficulty) with anchors at 2-point intervals.
The overall total score range is from 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
|
Baseline to Week 8
|
Change From Baseline in Clinical Global Impression of Severity (CGI-S) to Each Visit
Time Frame: Baseline to Weeks 1, 2, 3, 4, 6, 8
|
The CGI-Severity (CGI-S) consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?"
which is rated on the following seven-point scale: 1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.
|
Baseline to Weeks 1, 2, 3, 4, 6, 8
|
Clinical Global Impression - Improvement of Illness (CGI-I) Score at Last Study Visit
Time Frame: Week 8
|
The CGI-Improvement of Illness (CGI-I) consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse.
|
Week 8
|
Patient Global Impression - Improvement of Illness (PGI-I) Score at Last Study Visit
Time Frame: Week 8
|
The PGI-Improvement of Illness (PGI-I) consists of one question for the patient: "Since the start of the study, my overall status with regard to depression is?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse.
|
Week 8
|
Clinical Global Impression - Improvement of Illness (CGI-I) Responders at Last Study Visit
Time Frame: Week 8
|
Patients were responders if the CGI-I rating was "Much Improved" or "Very Much Improved".
The CGI-Improvement of Illness (CGI-I) consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse.
Results are expressed in number of patients.
|
Week 8
|
Patient Global Impression - Improvement of Illness (PGI-I) Responders at Last Study Visit
Time Frame: Week 8
|
Patients were responders if the PGI-I rating was "Much Improved" or "Very Much Improved".
The PGI-Improvement of Illness (PGI-I) consists of one question for the patient: "Since the start of the study, my overall status with regard to depression is?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse.
Results are expressed in number of patients.
|
Week 8
|
Overall Quality of Sleep at Each Visit
Time Frame: Weeks 1, 2, 3, 4, 6, 8
|
Overall Quality of Sleep was measured on a 4-point rating scale ranging from 1 = very poor to 4 = excellent in response to the question: "Since the last study visit, how would you rate the overall quality of your sleep?".
|
Weeks 1, 2, 3, 4, 6, 8
|
Trouble Falling Asleep at Each Visit
Time Frame: Weeks 1, 2, 3, 4, 6, 8
|
Trouble Falling Asleep was measured on a 4-point rating scale ranging from 1 = never to 4 = always in response to the question: "Since the last study visit, how often did you experience trouble falling asleep?".
|
Weeks 1, 2, 3, 4, 6, 8
|
Awakening During the Night at Each Visit
Time Frame: Weeks 1, 2, 3, 4, 6, 8
|
Awakening during the night was measured on a 4-point rating scale ranging from 1 = never to 4 = always in response to the question: "Since the last study visit did you awaken during the night?".
|
Weeks 1, 2, 3, 4, 6, 8
|
Discontinuation Due to Lack of Efficacy
Time Frame: Baseline to Week 8
|
Number of patients who discontinued due to lack of efficacy during the whole study period (8 weeks).
|
Baseline to Week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2007
Primary Completion (Actual)
November 1, 2007
Study Completion (Actual)
November 1, 2007
Study Registration Dates
First Submitted
October 17, 2008
First Submitted That Met QC Criteria
October 17, 2008
First Posted (Estimate)
October 20, 2008
Study Record Updates
Last Update Posted (Estimate)
April 27, 2012
Last Update Submitted That Met QC Criteria
April 24, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Anti-Anxiety Agents
- Antidepressive Agents, Second-Generation
- Trazodone
Other Study ID Numbers
- 04ACL3-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingMajor Depressive Disorder (MDD)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingMajor Depressive Disorder (MDD)China
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedSingle Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating TabletsMajor Depressive Disorder (MDD)India
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States